IN2015KN00657A - - Google Patents

Info

Publication number
IN2015KN00657A
IN2015KN00657A IN657KON2015A IN2015KN00657A IN 2015KN00657 A IN2015KN00657 A IN 2015KN00657A IN 657KON2015 A IN657KON2015 A IN 657KON2015A IN 2015KN00657 A IN2015KN00657 A IN 2015KN00657A
Authority
IN
India
Prior art keywords
rheumatoid arthritis
csf antibodies
mor103
dosages
administered
Prior art date
Application number
Inventor
Stefan Haertle
Stephane Leclair
Amgad Shebl
Stefan Steidl
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of IN2015KN00657A publication Critical patent/IN2015KN00657A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/243—Colony Stimulating Factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

The present invention provides anti-GM-CSF antibodies for use in the treatment of rheumatoid arthritis. Anti-GM-CSF antibodies, in particular MOR103, are administered to patients suffering from rheumatoid arthritis at dosages that are beneficial in a clinical setting.
IN657KON2015 2012-09-20 2013-09-19 IN2015KN00657A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12185235 2012-09-20
US201261703871P 2012-09-21 2012-09-21
PCT/EP2013/069501 WO2014044768A1 (en) 2012-09-20 2013-09-19 Treatment for rheumatoid arthritis

Publications (1)

Publication Number Publication Date
IN2015KN00657A true IN2015KN00657A (en) 2015-07-17

Family

ID=46963526

Family Applications (1)

Application Number Title Priority Date Filing Date
IN657KON2015 IN2015KN00657A (en) 2012-09-20 2013-09-19

Country Status (23)

Country Link
US (3) US20150246969A1 (en)
EP (3) EP3916013A1 (en)
JP (3) JP2015533806A (en)
KR (3) KR20220028177A (en)
CN (2) CN104995210A (en)
AU (2) AU2013320261A1 (en)
BR (1) BR112015006189B1 (en)
CA (1) CA2884124A1 (en)
CL (2) CL2015000696A1 (en)
CR (1) CR20150153A (en)
DO (1) DOP2015000070A (en)
EA (1) EA031489B1 (en)
HK (1) HK1208231A1 (en)
IL (1) IL237554B (en)
IN (1) IN2015KN00657A (en)
MA (1) MA37946B1 (en)
MX (2) MX2015003644A (en)
MY (1) MY175388A (en)
PE (1) PE20151079A1 (en)
PH (1) PH12015500591B1 (en)
SG (2) SG10201803778PA (en)
UA (1) UA117228C2 (en)
WO (1) WO2014044768A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10201803778PA (en) * 2012-09-20 2018-06-28 Morphosys Ag Treatment for rheumatoid arthritis
AR093297A1 (en) 2012-10-31 2015-05-27 Amgen Res (Munich) Gmbh LIQUID FORMULATION THAT INCLUDES A GM-CSF NEUTRALIZING COMPOUND
US9833410B2 (en) 2012-10-31 2017-12-05 Takeda Gmbh Lyophilized formulation comprising GM-CSF neutralizing compound
EP3039039B1 (en) * 2013-08-30 2021-03-10 Takeda GmbH Antibodies neutralizing gm-csf for use in the treatment of rheumatoid arthritis or as analgesics
WO2015138638A1 (en) * 2014-03-11 2015-09-17 Theraly Pharmaceuticals, Inc. Long acting trail receptor agonists for treatment of autoimmune diseases
EA201691883A1 (en) * 2014-05-07 2017-05-31 Такеда Гмбх LIQUID COMPOSITION CONTAINING A COMPOUND, NEUTRALIZING GM-CSF
GB201519331D0 (en) * 2015-11-02 2015-12-16 Glaxosmithkline Ip Dev Ltd Treatment paradigm
JP6797203B2 (en) 2015-12-17 2020-12-09 ザ・ジョンズ・ホプキンス・ユニバーシティー Improvement of systemic sclerosis by death receptor agonist
CN109195620B (en) 2016-04-07 2022-06-28 约翰霍普金斯大学 Compositions and methods for treating pancreatitis and pain with death receptor agonists
PL3328887T3 (en) * 2016-09-19 2021-12-27 I-Mab Biopharma (Hangzhou) Co., Ltd. Anti-gm-csf antibodies and uses thereof
EP3623382A1 (en) 2018-09-14 2020-03-18 Universität Zürich Ligands to gm-csf or gm-csf-receptor for use in leukemia in a patient having undergone allo-hct
US11655293B2 (en) 2018-02-22 2023-05-23 Universitat Zurich Ligands to GM-CSF or GM-CSF-receptor for use in leukemia in a patient having undergone allo-HCT
WO2021204649A1 (en) 2020-04-06 2021-10-14 Glaxosmithkline Intellectual Property Development Limited Gm-csf antagonists for use in the treatment of severe pulmonary covid-19, cytokine release syndrome and/or acute respiratory distress syndrome

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
KR100408229B1 (en) 1996-10-04 2003-12-01 암겐 인코포레이티드 Pharmaceutical compositions containing an mpl ligand
US7455836B2 (en) 2000-05-08 2008-11-25 The University Of Melbourne Method of treatment and agents useful for same
EP3620171B1 (en) * 2005-05-18 2022-04-20 MorphoSys AG Anti-gm-csf antibodies and uses therefor
CA2915270C (en) 2005-08-05 2017-07-11 Amgen Inc. Stable aqueous protein or antibody pharmaceutical formulations and their preparation
EP2010214A4 (en) * 2006-04-10 2010-06-16 Abbott Biotech Ltd Uses and compositions for treatment of rheumatoid arthritis
US8093360B2 (en) * 2006-09-28 2012-01-10 Elusys Therapeutics, Inc. Antibodies that bind B. anthracis exotoxin, formulations thereof, and methods of use
ES2432173T3 (en) * 2006-11-21 2013-12-02 Kalobios Pharmaceuticals, Inc. Methods of treating chronic inflammatory diseases using a GM-CSF antagonist
BRPI0809674A2 (en) * 2007-03-30 2014-10-07 Medimmune Llc WATER FORMULATION, STERILE, STABLE, PHARMACEUTICAL UNIT FORM, SEALED CONTAINER, KIT, METHOD TO PREVENT, CONTROL, TREAT OR IMPROVE INFLAMMATORY DISORDER, COMPOSITION, PROCESS FOR PREPARATION, PREPARATION FOR PREPARATION, PREPARATION AND PREPARATION
EP2137325A1 (en) * 2007-04-02 2009-12-30 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
AU2008235044B2 (en) 2007-04-05 2011-08-25 Sandoz Ag Stable aqueous G-CSF formulations
WO2008157282A1 (en) * 2007-06-18 2008-12-24 Genentech, Inc. Biological markers predictive of rheumatoid arthritis response to b-cell antagonists
TW200918553A (en) * 2007-09-18 2009-05-01 Amgen Inc Human GM-CSF antigen binding proteins
KR20100102108A (en) 2007-11-13 2010-09-20 에베크 인코포레이티드 Monoclonal antibodies that bind to hgm-csf and medical compositions comprising same
EP2196476A1 (en) * 2008-12-10 2010-06-16 Novartis Ag Antibody formulation
CA2746827C (en) 2008-12-22 2018-01-23 The University Of Melbourne Osteoarthritis treatment
CN108014335A (en) * 2008-12-22 2018-05-11 墨尔本大学 The purposes of the antagonist of granulocyte macrophage colony stimulating factor
JP2010241718A (en) 2009-04-03 2010-10-28 Kyowa Hakko Kirin Co Ltd Stable aqueous solution preparation of antibody
CA2760755A1 (en) * 2009-05-05 2010-11-11 Morphosys Ag Treatment for multiple sclerosis
RS53010B (en) 2009-12-31 2014-04-30 Arven Ilac Sanayi Ve Ticaret A.S. A novel process for preparing g-csf (granulocyte colony stimulating factor)
CN105521491B (en) * 2010-03-01 2020-03-24 西托戴恩有限公司 Concentrated protein formulations and uses thereof
RU2013156435A (en) 2011-07-06 2015-08-20 МорфоСис АГ THERAPEUTIC COMBINATIONS ANTI-CD20 AND ANTI-GM-CSF ANTIBODIES AND THEIR APPLICATIONS
SG10201803778PA (en) * 2012-09-20 2018-06-28 Morphosys Ag Treatment for rheumatoid arthritis

Also Published As

Publication number Publication date
PH12015500591A1 (en) 2015-05-11
SG10201803778PA (en) 2018-06-28
PH12015500591B1 (en) 2015-05-11
IL237554B (en) 2019-12-31
EP2897977A1 (en) 2015-07-29
DOP2015000070A (en) 2015-08-16
KR20230041086A (en) 2023-03-23
JP2022169709A (en) 2022-11-09
PE20151079A1 (en) 2015-08-07
JP2015533806A (en) 2015-11-26
US20180230208A1 (en) 2018-08-16
MX2021006111A (en) 2021-07-07
MX2015003644A (en) 2015-09-25
UA117228C2 (en) 2018-07-10
MY175388A (en) 2020-06-23
SG11201501595YA (en) 2015-05-28
KR20220028177A (en) 2022-03-08
BR112015006189A2 (en) 2019-11-26
CA2884124A1 (en) 2014-03-27
CL2015000696A1 (en) 2015-10-23
US20150246969A1 (en) 2015-09-03
EA031489B1 (en) 2019-01-31
EP3916013A1 (en) 2021-12-01
CN109999195A (en) 2019-07-12
AU2016250388A1 (en) 2016-11-17
EA201590359A1 (en) 2015-08-31
EP3345923A1 (en) 2018-07-11
CR20150153A (en) 2015-09-14
BR112015006189B1 (en) 2022-04-05
KR20150056846A (en) 2015-05-27
AU2016250388B2 (en) 2018-07-19
CL2018000933A1 (en) 2018-07-20
WO2014044768A1 (en) 2014-03-27
AU2013320261A1 (en) 2015-04-09
MA37946B1 (en) 2018-09-28
JP2018138551A (en) 2018-09-06
US10913792B2 (en) 2021-02-09
US20210130451A1 (en) 2021-05-06
MA37946A1 (en) 2018-01-31
HK1208231A1 (en) 2016-02-26
CN104995210A (en) 2015-10-21
IL237554A0 (en) 2015-04-30

Similar Documents

Publication Publication Date Title
MX2021006111A (en) Treatment for rheumatoid arthritis.
IL276434A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
IL279330A (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX342810B (en) Anti-il-6 receptor antibodies and methods of use.
NZ630542A (en) Methods of treating a tauopathy
MX2020010693A (en) Use of long-acting glp-1 peptides.
UA113403C2 (en) METHOD OF IMPROVING THE EFFICIENCY OF FOLR1 CANCER THERAPY
EA201400623A1 (en) NEW 2H-INDASOLS AS ANTAGONISTS EP EPCEPTOR
MX2017003216A (en) Use of il-17 antagonists to inhibit the progression of structural damage in psoriatic arthritis patients.
ME02932B (en) Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
MX2013003168A (en) Anti-ephrin-b2 antibody and use thereof.
MX2019008148A (en) Use of long-acting glp-1 peptides.
UA97054C2 (en) Method for the treatment of patients with dependence owing to application of psychoactive substances
UA74882U (en) Pharmaceutical composition for treatment of sexual dysfunction